Non-small cell lung cancer with single brain metastasis: the role of surgical treatment

被引:58
|
作者
Granone, P [1 ]
Margaritora, S [1 ]
D'Andrilli, A [1 ]
Cesario, A [1 ]
Kawamukai, K [1 ]
Meacci, E [1 ]
机构
[1] Univ Cattolica Sacro Cuore, A Gemelli Hosp, Dept Gen Surg, I-00168 Rome, Italy
关键词
lung cancer; brain metastasis; surgical treatment;
D O I
10.1016/S1010-7940(01)00744-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The prognosis of non-small cell lung cancer (NSCLC) with brain metastasis is very poor, with median survival rate below 6 months, even if treated with palliative radio and/or chemotherapy. To assess the effectiveness of surgical treatment for this kind of patients we reviewed our experience. Methods: From January 1989 to October 1999, 30 patients (26 males and four females; mean age: 58.7 years) with NSCLC and single brain metastasis underwent surgical treatment of both primary lung cancer and secondary cerebral lesion. Patients (pts) were divided into two major groups. In group I (Gl) 20 pts (18 males and two females) presented a synchronous brain metastasis. In group 2 (G2) 10 pts (eight males and two females) presented a metachronous brain metastasis during the follow-up period (range 3-24 months since the primary tumor). Patients selected in GI had T1-2, N0-1 clinical staging, good 'performance status' (ECOG:0-1; Karnofsky index > 70%), age < 75 years. Craniotomy has always been the first approach. In G2 also patients with locally advanced tumors T3 and/or N2) were included. Whole brain radiotherapy and/or chemotherapy was the post-operative choice treatment. Results: Histologic findings have shown: adenocarcinoma in 17 cases (12 in Gl; five in G2), squamous cell carcinoma in 10 cases (six in G1; four in G2), large cell carcinoma in 2 (one in Gl; one in G2) and large cell neuroendocrine carcinoma in one (Gl). Survival analysis (Kaplan-Meier method) has shown an overall value of 80% at 1 year (95% in G1; 50% in G2), 41% at 2 years (47% in G1; 30% in G2) and 17% at 3 years (14% in G1; 20% in G2). Overall median survival is 23 months (23 in G1; 11 in G2); mean survival 27.8 months (30.3 months in G1; 22.8 months in G2). According to univariate analysis prognosis is definitively better in N0 tumors compared to N1-2 tumors and in adenocarcinoma cases compared to other histotypes (P < 0.05). Conclusions: We can conclude that combined surgical therapy is, nowadays, the choice treatment for this kind of patients, even though restricted to selected cases. The knowledge of prognostic factors may optimize indications for surgery. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [21] Prognosis of non-small cell lung cancer patients with brain metastasis
    Ohhara, Yoshihito
    Isobe, Hiroshi
    Sato, Toshitaka
    Ito, Kenichiro
    Fuke, Satoshi
    Kojima, Tetsuya
    Saito, Hiroshi
    Nishiura, Yoichi
    ANNALS OF ONCOLOGY, 2015, 26 : 106 - 106
  • [22] Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer
    Qing Li
    Zhen Lin
    Ye Hong
    Yang Fu
    Yueyun Chen
    Ting Liu
    Yue Zheng
    Jiangfang Tian
    Chunhua Liu
    Wei Pu
    Zhenyu Ding
    Chun Wang
    Scientific Reports, 12
  • [23] Association of brain metastasis in non-small cell lung cancer.
    Zhao, Yu
    Guo, Huiqin
    Lu, Jiangyang
    Christiani, David C.
    Lin, Xihong
    Wang, Zhaoxi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center
    Kimura, Keisuke
    Deguchi, Shoichi
    Mitsuya, Koichi
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Ko, Ryo
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Hayashi, Nakamasa
    JOURNAL OF NEURO-ONCOLOGY, 2023, 162 (02) : 435 - 441
  • [25] Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center
    Keisuke Kimura
    Shoichi Deguchi
    Koichi Mitsuya
    Nobuaki Mamesaya
    Haruki Kobayashi
    Ryo Ko
    Kazushige Wakuda
    Akira Ono
    Hirotsugu Kenmotsu
    Tateaki Naito
    Haruyasu Murakami
    Toshiaki Takahashi
    Nakamasa Hayashi
    Journal of Neuro-Oncology, 2023, 162 : 435 - 441
  • [26] Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer
    Robins, H. Ian
    Traynor, Anne M.
    Mehta, Minesh
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (07) : 732 - 733
  • [27] Surgical treatment of non-small cell lung cancer with isolated synchronous brain metastases
    Hoseok, I
    Lee, JII
    Nam, DH
    Ahn, YC
    Shim, YM
    Kim, K
    Choi, YS
    Kim, J
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2006, 21 (02) : 236 - 241
  • [28] Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer
    Gao, Xin-Liang
    Zhang, Ke-Wei
    Tang, Ming-Bo
    Zhang, Ke-Jian
    Fang, Li-Nan
    Liu, Wei
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2017, 24 (01) : 1 - 7
  • [29] Outcomes of surgical treatment for isolated adrenal metastasis from non-small cell lung cancer
    Buero, Agustin
    Nardi, Walter S.
    Chimondeguy, Domingo J.
    Pankl, Leonardo G.
    Lyons, Gustavo A.
    Arboit, David Gonzalez
    Quildrian, Sergio
    ECANCERMEDICALSCIENCE, 2021, 15
  • [30] Surgical treatment of solitary metastasis in the male breast from non-small cell lung cancer
    Gomez-Caro, Abel
    Pinero, Antonio
    Roca, Maria Jose
    Torres, Juan
    Ferri, Belen
    Galindo, Pedro J.
    Parrilla, Pascual
    BREAST JOURNAL, 2006, 12 (04): : 366 - 367